Viridian Q2 net loss $65M; THRIVE topline readout on track for Sept 2024; cash $571.4M

Viridian Therapeutics, Inc.\DE

2024-Q2 EPS reported -$1.82 revenue$144,000

Net loss of $65.0M in Q2 2024 vs $55.1M Q2 2023; cash balance $571.4M as of June 30, 2024.
THRIVE phase 3 (active TED) topline data for VRDN-001 expected September 2024.
THRIVE-2 (chronic TED) enrollment completed with 188 patients, exceeding 159 target; topline due year-end 2024.
REVEAL-1 and REVEAL-2 phase 3 trials for subcutaneous VRDN-003 to initiate August 2024; topline data H1 2026.
IND for VRDN-006 (FcRn inhibitor) on track for year-end 2024; NHP data for VRDN-008 expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.